Awz Ventures
VC Fund
Toronto, Canada
Awz Ventures is a VC fund in Toronto focused on Software and Machine Learning. AWZ is a Canadian corporation that imports knowledge, know-how and technology from Israel, a global leader in the homeland security sector, to advance and implement state-of-the-art, integrated, customized and comprehensive cyber security, intelligence, and physical security solutions and services for business and government in Canada and globally
- Total investments:
- 26
- Last investment:
- Lead investor:
- 62%
Last updated:
For AI agents: llms.txt
Industries Awz Ventures invests in
Stages Awz Ventures invests in
Countries Awz Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $4M–$10M
- Series A
- $2.5M–$10M
Investment Focus
Industry
- Software 9 (35%)
- Machine Learning 6 (23%)
- Artificial Intelligence 6 (23%)
- Cyber Security 5 (19%)
- Security 3 (12%)
Stage
- Seed 9 (35%)
- Series A 6 (23%)
- Funding Round 4 (15%)
- Series B 2 (8%)
- Series C 1 (4%)
Country
- Israel 16 (62%)
- Canada 1 (4%)
- United States 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
| CFO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Promise Bio
|
Promise Bio develops a virtual AI platform that helps to identify multiple Post-Translational Modifications in proteins from a single blood sample. It helps to cure chronic diseases. | $8.3M / Seed / Oct 23, 2024 | |
|
Promise Bio
|
Promise Bio develops a virtual AI platform that helps to identify multiple Post-Translational Modifications in proteins from a single blood sample. It helps to cure chronic diseases. | $8.3M / Seed / Oct 23, 2024 | |
NanoPass Technologies
|
NanoPass is continuously engaged in joint clinical development with top pharmaceutical companies, to demonstrate the benefits of its technology for various indications. | $4M / Seed / Jul 15, 2024 | |
DeepKeep
|
DeepKeep safeguards artificial intelligence with AI-native security and trustworthiness from the R&D phase of machine learning models through to deployment, covering risk assessment, prevention, detection and mitigation. Only AI-native security, built itself with generative AI, can protect the complexity and innovation speed of diverse sourcedomains, models and datasets. DeepKeep's AI security promotes secure, unbiased, error-free, transparent, explainable and trustworthy AI solutions for vision data models, LLM and tabular models. | $10M / Seed / May 01, 2024 | |
|
DeepKeep
|
DeepKeep safeguards artificial intelligence with AI-native security and trustworthiness from the R&D phase of machine learning models through to deployment, covering risk assessment, prevention, detection and mitigation. Only AI-native security, built itself with generative AI, can protect the complexity and innovation speed of diverse sourcedomains, models and datasets. DeepKeep's AI security promotes secure, unbiased, error-free, transparent, explainable and trustworthy AI solutions for vision data models, LLM and tabular models. | $10M / Seed / May 01, 2024 | |
KTrust
|
At KTrust, we redefine Kubernetes (K8s) security. Mastering K8s attack flows, we uncover innovative paths, validate real exposures, and automate mitigation for your unique ecosystem. Our K8s-native Continuous Threat Exposure Management (CTEM) approach blends CVEs, MITRE, and unique K8s attack flows, ensuring K8s-first businesses stay ahead ofevolving threats. Our platform offers comprehensive K8s Risk Prioritization, Breach and Attack Simulation, and Ransomware Protection – all consolidated in one place. We guarantee the security and validation of your K8s exposure ecosystem. | $5.3M / Seed / Feb 14, 2024 | |
CitrusX
|
Citrusx is a trusted end-to-end platform for AI transparency and explainability helping organizations develop confidence in their models. | $4.5M / Seed / Dec 11, 2023 | |
101 Therapeutics
|
101 Therapeutics is a Phase II pharmaceutical company on a mission to cure infectious diseases by targeting the pathology not the the pathogen. After a successful Phase I safety trial, 101 Therapeutics is conducting a Phase II efficacy trials for its targeted COVID-19 therapy. | $10M / Series A / Oct 01, 2022 | |
Classiq Technologies
|
Classiq Technologies, the leading quantum software company, provides an all-encompassing software platform (IDE, compiler and OS) with a single point of entry into quantum computing, from algorithm design to execution. Tailored to all levels of developer proficiency, Classiq aims to democratize access to quantum computing with software that equipscustomers to take full advantage of the quantum computing revolution. A low-code development environment that automates quantum programming ensures that a broader range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of how to program quantum computer hardware. Classiq also works closely with advanced computation hardware providers providing software for use with quantum computers, HPC and quantum simulators. Backed by powerful investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking software development platform. | $13M / Series B / Sep 30, 2022 | |
Pentera
|
Pentera provides an automated penetration-testing platform that assesses and reduces corporate cybersecurity risks.By applying the Hacker’s perspective, the software identifies, analyzes, and remediates cyber defense vulnerabilities. Security officers and service providers use its platform to perform continuous machine-based penetration tests andimprove their immunity against cyberattacks across their organizational networks.The Petah Tiqva, HaMerka-based company was founded by Arik Faingold and Arik Liberzon in 2015. | $150M / Series C / Jan 11, 2022 | |
| See all 26 investments → | |||
Co-Investors
Blackstone
5 deals together
AstraZeneca
2 deals together
Blackstone Innovations Investments
2 deals together
Insight Partners
2 deals together
Pfizer
2 deals together
Evolution Equity Partners
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Awz Ventures invest in?
Awz Ventures invests primarily in Software, Machine Learning and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 26 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Awz Ventures's check size?
Awz Ventures typically joins rounds of $4M–$10M at Seed and $2.5M–$10M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Awz Ventures participates in.
How do I contact Awz Ventures?
Public channels for Awz Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Awz Ventures?
The team at Awz Ventures includes Michael Fromstein (CFO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
